SBIR/STTR PHASE I: NMR Properties of Carbon Nanomaterials for Medical Applications

SBIR/STTR 第一阶段：医疗应用碳纳米材料的 NMR 特性

• 批准号: 0128263
• 负责人: Steven Stevenson
• 金额: $ 9.99万
• 依托单位: Luna Innovations, Incorporated
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-01-01 至 2002-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0128263&HistoricalAwards=false
• 关键词: SBIR; STTR; PHASE; NMR; Properties

This Small Business Technology Transfer Phase I project will develop novel trimetallic nitride template endohedral fullerene (TNTs) materials for use as contrast agents in magnetic resonance imaging (MRI). TNTs, which offer significant diagnostic and therapeutic possibilities, are now available in sufficient research quantities. Chemical functionalization reactions to solubilize the TNTs are also now available. TNTs offer an exciting alternative to current MRI contrast agents. TNTs offer the flexibility of excapsulating a variety of paramagnetic metals into the C80 fullerene cage. As several of the metals are paramagnetic, a production optimization plan balancing cost of materials versus efficiency as an MRI contrast agent is a primary focus of this project. The development of TNT based contrast agents is expected to lead to smaller patient doses, increased T1 relaxation rates and increased product safety.The commercial application of this project is in the contrast agent segment of the MRI imaging market. If successful, this project could result in a significant expansion in MRI capability and usage, with the potential of developing new business on the order of $700 million per year.

该小企业技术转让第一阶段项目将开发新型三金属氮化物模板内嵌富勒烯（TNT）材料，用作磁共振成像（MRI）的造影剂。TNT提供了重要的诊断和治疗可能性，目前已有足够的研究数量。溶解TNT的化学官能化反应现在也是可用的。TNT为目前的MRI造影剂提供了一种令人兴奋的替代品。TNT提供了将各种顺磁性金属封装到C80富勒烯笼中的灵活性。由于几种金属是顺磁性的，因此平衡材料成本与MRI造影剂效率的生产优化计划是该项目的主要重点。基于TNT的造影剂的开发预计将导致更小的患者剂量，增加T1弛豫率和增加产品安全性。该项目的商业应用是在MRI成像市场的造影剂部分。如果成功，该项目可能会导致MRI能力和使用的显着扩展，并有可能开发每年7亿美元的新业务。